- Home
- Drug And Medication Industry
- Eli Lilly And Market and Forecasts, May 2013
Industries
- Drug and Medication (72)
- Pathology (52)
- Pharmaceutical (24)
- Drug Discovery and Development (23)
- Biopharmaceutical (9)
-
- Biotechnology (9)
- Meat and Poultry (6)
- Biological Therapy (5)
- Diagnostics (5)
- Managed Care (5)
- Medical Facility (5)
- Energy & Environment (4)
- Generic Drug (4)
- Genomics (4)
- Veterinary Healthcare (4)
- Chemical (3)
- Drug Delivery Technology (3)
- Nanotechnology (3)
- Pharmacies and Drug Stores (3)
- Research and Development (3)
Top countries
Publication dates
All regions
data types
- All
- Company Data (1 479)
- Industry Data
- Country Data (217)
Eli Lilly And Market and Forecasts, May 2013
industry reports
» Download Public Reports
1-10 of about 300 reports for Eli Lilly And
U.S. Veterinary Healthcare Industry Brief
- Industry report
- June 2011
- 16 pages
- by Corporation
... lilly and company elanco and lilly elanco and lilly S connection is clear and strong Synergies Differences yg yg Regulated businesses cdbf Predictable regulatory pathways Connected to y way o ...
- Industries: Veterinary Healthcare
- Countries: United States
Testosterone in Australia : Innovation and Technology Trends
- Industry report
- August 2011
- 17 pages
- by Corporation
... lilly and company us market understanding payer environment note: most payers wait about 9-12 months post launch to review & add new products.For personal use only 9 acrux investment community ...
- Industries: Drug and Medication
- Countries: Australia
Pharmaceutical in Indonesia : Innovation and Technology Trends
- Industry report
- December 2012
- 22 pages
... Aventis wyeth pfizer astraz astraz boe.Ing bristol-m s eli lilly boe.Ing pharmaceutical sales and market share worldwide novartis ag is projected to lead the global market in 2016-2018 2011 r&d spending ...
- Industries: Pharmaceutical
- Countries: Indonesia
Medicine Market Brief
- Industry report
- February 2011
- 17 pages
- by Intergovernmental Agency
... Even as we rebuild our r&d engine, we must build an environment where pharmaceutical innovation can thrive john lechleiter (ceo eli lilly) 10 february 2011 circlecopyrt ifpma 2012 global r ...
- Industries: Drug and Medication
Insulin Business in The United Kingdom and Canada
- Industry report
- April 2012
- 2 pages
... Indistinguishable from eli lilly's humulin r, as sembiosys had previously shown in animals Sbs-1000 was well tolerated at pharmacologically active dosages #110, 2985 - 23rd ave ne calgary, ab canada t1 ...
- Industries: Drug and Medication
- Countries: United Kingdom, Canada
U.S. Pharmaceutical Business : Innovation and Technology Trends
- Industry report
- August 2011
- 24 pages
... Refutes report that valeant has made Bayer, trius to develop skin, pneumonia antibiotic Lupin in pact to sell eli lilly's diabetes products in india legal & compliance Us appeals court ...
- Industries: Pharmaceutical
- Countries: United States
The Chinese Insulin Market : Key Market Figures
- Industry report
- May 2011
- 49 pages
- by Corporation
... Ims, monthly mat volume figures novo nordisk sanofi-aventis eli lilly conversion rate to modern insulin i nsulin ma rket share (v ol u m e) short acting segment premix segment long acting segment feb ...
- Industries: Drug and Medication
- Countries: China
Pharmaceutical in The United States : Innovation and Technology Trends
- Industry report
- May 2012
- 13 pages
... D - ada mark deeg, md - eli lilly and company deborah demanno, phd - takeda victor dishy, md - daiichi sankyo joseph frascella, phd - national institute on drug abuse, nih david fryburg, md - roi bio ...
- Industries: Pathology
- Countries: United States
Pharmaceutical Business Overview
- Industry report
- December 2012
- 21 pages
- by Corporation
... Sanofi merck bms gsk novartis eli lilly abbott bayer source: company reports, roche analysis; figures based on fiscal year 2011 financials phase ii (24 nmes) phase iii (8 nmes) registration (3 nmes ...
- Industries: Pathology
Drug Development Business Brief
- Industry report
- May 2012
- 12 pages
... Affect your business. Before making any or taking any action that may affect your business, you should consult a qualified professional advisor. Neither deloitte fas nor eli lilly shall ...
- Industries: Drug Discovery and Development
Reportlinker.com © Copyright 2013. All rights reserved.
